Adapted from Klaus et al Sci Rep. 2018 Jan 11;8(1):519.IgM is a multivalent antibody which evolved as a first line defense of adaptive immunity. It consists of heavy and light chains assembled into a complex oligomer. In mouse serum there are two forms of IgM, a full-length and a truncated one. The latter contains ÄÂ?’ […]
| Inventor | Institute |
|---|---|
| Tomasz Klaus ; Monika Bzowska ; Joanna Bereta | Jagiellonian University |
| Cat. #: | 160644 |
|---|---|
| Unit size: | 100 ug |
| Research Fields: | Other |
| Application: | ELISA ; Fn ; WB |
| Target: | Human blood group B antigen |
| Reactivity: | Human |
| Host: | Mouse |
| Class: | Recombinant |
| Product description: | Adapted from Klaus et al Sci Rep. 2018 Jan 11;8(1):519.IgM is a multivalent antibody which evolved as a first line defense of adaptive immunity. It consists of heavy and light chains assembled into a complex oligomer. In mouse serum there are two forms of IgM, a full-length and a truncated one. The latter contains ÄÂ?' chain, which lacks a variable region. Although ÄÂ?' chain was discovered many years ago, its origin has not yet been elucidated. The inventing PI's results indicate that ÄÂ?' chain is generated from a full-length heavy chain by non-enzymatic cleavage of the protein backbone. The cleavage occurred specifically after Asn209 and is prevented by mutating this residue into any other amino acid. The process requires the presence of other proteins, preferentially with an acidic isoelectric point, and is facilitated by neutral or alkaline pH. This unique characteristic of the investigated phenomenon distinguishes it from other, already described, Asn-dependent protein reactions. A single IgM molecule is able to bind up to 12 epitopes via its antigen binding fragments (Fabs). The cleavage at Asn209 generates truncated IgM molecules and free Fabs, resulting in a reduced IgM valence and probably affecting IgM functionality in vivo. |
|---|---|
| Conjugation: | Unconjugated |
| Isotype: | IgM |
| Immunogen: | various |
| Immunogen Uniprot ID: | various |
| Target background: | Adapted from Klaus et al Sci Rep. 2018 Jan 11;8(1):519. IgM is a multivalent antibody which evolved as a first line defense of adaptive immunity. It consists of heavy and light chains assembled into a complex oligomer. In mouse serum there are two forms of IgM, a full-length and a truncated one. The latter contains ÄÂ?' chain, which lacks a variable region. Although ÄÂ?' chain was discovered many years ago, its origin has not yet been elucidated. The inventing PI's results indicate that … |
|---|
| Format: | Liquid |
|---|---|
| Shipping conditions: | Dry ice |
| References: |
Klaus et al. 2018. Sci Rep. 8(1):519. PMID: 29323348. IgM with improved stability and method for obtaining it and applications |
|---|
| Cat. # | Tool Name | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 151019 | Anti-Mos [S3.1] |
Key Info
Anti-Mos [S3.1]
|
View Tool | |||||||||||||||||||
| 151026 | Anti-FCGR1 [10.1] mAb |
Key Info
Anti-FCGR1 [10.1] mAb
|
View Tool | |||||||||||||||||||
| 151036 | Anti-ICAM1 [15.2] |
Key Info
Anti-ICAM1 [15.2]
|
View Tool | |||||||||||||||||||
| 151040 | Anti-CD11 & CD18 [24] |
Key Info
Anti-CD11 & CD18 [24]
|
View Tool | |||||||||||||||||||
| 151035 | Anti-CD8 [14] mAb |
Key Info
Anti-CD8 [14] mAb
|
View Tool | |||||||||||||||||||
Please note we may take up to three days to respond to your enquiry.
CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.